| |
| |
|
| Insider
Information: |
Morrison Briggs |
| Relationship: |
Director |
| City: |
Waltham |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
6 |
|
| Direct
Shares |
92,071 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$1,445,124 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
92,071 |
|
|
| Total
Value |
$1,445,124 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
2
|
7
|
|
Stock
price went up :
|
2
|
4
|
| Stock
price went down : |
0
|
3
|
| |
|
|
|
Gain/Loss Ratio : |
2.0
|
1.3
|
| Percentage
Gain/Loss : |
 52.4%
|
 -14.6%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Syndax Pharmaceuticals Inc |
SNDX |
|
2024-02-07 |
34,836 |
|
0 |
Premium* |
|
|
Arvinas Holding Company, Llc |
ARVN |
Director |
2022-04-14 |
19,976 |
|
0 |
Premium* |
|
|
Repare Therapeutics Inc. |
RPTX |
Director |
2020-06-23 |
4,800 |
2020-06-23 |
0 |
Premium* |
|
|
Codiak Biosciences, Inc. |
CDAK |
Director |
2021-02-17 |
4,761 |
2021-02-17 |
0 |
Premium* |
|
|
Werewolf Therapeutics, Inc. |
HOWL |
Director |
2021-04-29 |
15,523 |
|
0 |
Premium* |
|
|
Carisma Therapeutics Inc |
CARM |
Director |
2023-03-07 |
12,175 |
2023-03-07 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| SNDX |
Syndax Pharmaceuticals In... |
|
– • – |
2024-02-07 |
4 |
A |
$0.00 |
$0 |
D/D |
17,000 |
34,836 |
0 |
- |
|
| SNDX |
Syndax Pharmaceuticals In... |
|
– • – |
2023-08-09 |
4 |
S |
$18.27 |
$965,402 |
D/D |
(52,855) |
17,836 |
0 |
% |
|
| SNDX |
Syndax Pharmaceuticals In... |
|
– • – |
2023-08-09 |
4 |
OE |
$8.77 |
$463,538 |
D/D |
52,855 |
70,691 |
0 |
- |
|
| SNDX |
Syndax Pharmaceuticals In... |
|
– • – |
2023-07-10 |
4 |
S |
$20.40 |
$1,078,068 |
D/D |
(52,855) |
17,836 |
0 |
% |
|
| SNDX |
Syndax Pharmaceuticals In... |
|
– • – |
2023-07-10 |
4 |
OE |
$8.77 |
$463,538 |
D/D |
52,855 |
70,691 |
0 |
- |
|
| SNDX |
Syndax Pharmaceuticals In... |
|
– • – |
2023-06-09 |
4 |
S |
$21.18 |
$1,119,421 |
D/D |
(52,855) |
17,836 |
0 |
% |
|
| SNDX |
Syndax Pharmaceuticals In... |
|
– • – |
2023-06-09 |
4 |
OE |
$6.38 |
$404,787 |
D/D |
52,855 |
70,691 |
0 |
- |
|
| SNDX |
Syndax Pharmaceuticals In... |
|
– • – |
2023-05-09 |
4 |
OE |
$6.38 |
$337,215 |
D/D |
52,855 |
70,691 |
0 |
- |
|
| SNDX |
Syndax Pharmaceuticals In... |
|
– • – |
2023-05-09 |
4 |
S |
$21.41 |
$1,131,478 |
D/D |
(52,855) |
17,836 |
0 |
% |
|
| SNDX |
Syndax Pharmaceuticals In... |
|
– • – |
2023-04-10 |
4 |
S |
$19.53 |
$1,032,237 |
D/D |
(52,855) |
17,836 |
0 |
% |
|
| SNDX |
Syndax Pharmaceuticals In... |
|
– • – |
2023-04-10 |
4 |
OE |
$6.38 |
$337,215 |
D/D |
52,855 |
70,691 |
0 |
- |
|
| SNDX |
Syndax Pharmaceuticals In... |
President, Head of R&D |
• • – |
2023-03-13 |
4 |
AS |
$22.53 |
$1,190,674 |
D/D |
(52,854) |
17,836 |
0 |
% |
|
| SNDX |
Syndax Pharmaceuticals In... |
President, Head of R&D |
• • – |
2023-03-13 |
4 |
OE |
$6.38 |
$337,209 |
D/D |
52,854 |
70,690 |
0 |
- |
|
| CARM |
Carisma Therapeutics Inc |
Director |
– • – |
2023-03-07 |
4 |
A |
$0.00 |
$0 |
D/D |
12,175 |
12,175 |
0 |
- |
|
| SNDX |
Syndax Pharmaceuticals In... |
President, Head of R&D |
• • – |
2023-02-06 |
4 |
OE |
$6.38 |
$337,209 |
D/D |
52,854 |
70,690 |
0 |
- |
|
| SNDX |
Syndax Pharmaceuticals In... |
President, Head of R&D |
• • – |
2023-02-06 |
4 |
AS |
$26.83 |
$1,417,909 |
D/D |
(52,854) |
17,836 |
0 |
% |
|
| SNDX |
Syndax Pharmaceuticals In... |
President, Head of R&D |
• • – |
2022-09-20 |
4 |
AS |
$23.25 |
$1,387,012 |
D/D |
(59,649) |
17,836 |
0 |
% |
|
| SNDX |
Syndax Pharmaceuticals In... |
President, Head of R&D |
• • – |
2022-09-20 |
4 |
OE |
$10.90 |
$650,174 |
D/D |
59,649 |
77,485 |
0 |
- |
|
| SNDX |
Syndax Pharmaceuticals In... |
President, Head of R&D |
• • – |
2022-09-19 |
4 |
AS |
$23.03 |
$2,633,044 |
D/D |
(114,339) |
17,836 |
0 |
% |
|
| SNDX |
Syndax Pharmaceuticals In... |
President, Head of R&D |
• • – |
2022-09-19 |
4 |
OE |
$10.90 |
$1,246,295 |
D/D |
114,339 |
132,175 |
0 |
- |
|
| SNDX |
Syndax Pharmaceuticals In... |
President, Head of R&D |
• • – |
2022-09-16 |
4 |
OE |
$7.20 |
$1,096,226 |
D/D |
125,000 |
70,870 |
0 |
- |
|
| SNDX |
Syndax Pharmaceuticals In... |
President, Head of R&D |
• • – |
2022-09-16 |
4 |
AS |
$23.22 |
$2,902,438 |
D/D |
(125,000) |
17,836 |
0 |
% |
|
| SNDX |
Syndax Pharmaceuticals In... |
President, Head of R&D |
• • – |
2022-09-15 |
4 |
AS |
$24.20 |
$1,616,035 |
D/D |
(66,775) |
17,836 |
0 |
% |
|
| SNDX |
Syndax Pharmaceuticals In... |
President, Head of R&D |
• • – |
2022-09-15 |
4 |
OE |
$7.20 |
$480,780 |
D/D |
66,775 |
84,611 |
0 |
- |
|
| SNDX |
Syndax Pharmaceuticals In... |
President, Head of R&D |
• • – |
2022-09-14 |
4 |
AS |
$23.80 |
$2,085,855 |
D/D |
(87,645) |
17,836 |
0 |
% |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
